Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICORDA study of high-dose inhaled corticosteroids versus triple therapy in uncontrolled T2-high asthma
2022-001805-40Phase 4Active
- Sponsor
- Hospital Universitario Lucus Augusti
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of budesonide, beclomethasone, mometasone, fluticasone, fluticasone propionate and 2 more in asthma (2 arms), sponsored by Hospital Universitario Lucus Augusti. Primary endpoint: Percentage of patients controlled at week 52. Started Mar 2023; status: active.
02
Drugs
budesonidebeclomethasonemometasonefluticasonefluticasone propionate
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-001805-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001805-40.